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1. INTRODUCTION {#jmv25910-sec-0050}
===============

Wuhan, China, became the center of an outbreak of the coronavirus disease 2019 (COVID‐19) in late December 2019. The epidemic of COVID‐19 has spread to the whole world within a short time. According to reports from the World Health Organization (WHO), up to 24:00 on 16 March 2020, a total of 80 881 confirmed cases and 3226 deaths were reported in China.[^1^](#jmv25910-bib-0001){ref-type="ref"} In addition, COVID‐19 has affected 150 countries, with 86 438 confirmed cases and 3388 deaths outside China.[^2^](#jmv25910-bib-0002){ref-type="ref"} With the further spread of COVID‐19, the confirmed cases of COVID‐19 in Korea, Japan, Spain, Italy, Iran, and other countries increased rapidly. The number of new confirmed cases, the cumulative number of confirmed cases, and deaths reported in the world outside China have surpassed that in China. COVID‐19 has become a serious threat to global health and a significant challenge to healthcare systems worldwide.

As a new infectious disease, there is no effective drugs and the vaccine is under development. Early detection, isolation, and treatment can maximize the control the spread of the disease among population. The current gold standard for COVID‐19 diagnosis is positive results of the nucleic acid amplification test (NAAT). However, there were many cases of positive results be confirmed after repeated NAAT negative,[^3^](#jmv25910-bib-0003){ref-type="ref"} and there were asymptomatic infections in patients with COVID‐19.[^4^](#jmv25910-bib-0004){ref-type="ref"}, [^5^](#jmv25910-bib-0005){ref-type="ref"} Asymptomatic infections may also become a new source of infection. Therefore, quickly and effectively diagnosing infections play a key role in preventing and controlling the epidemic. The guideline for the diagnosis and treatment of COVID‐19 (Trial edition Fifth), issued on 4 February, added clinical diagnostic criteria, that was, the suspected cases with typical imaging features in Hubei were clinically diagnosed cases.[^6^](#jmv25910-bib-0006){ref-type="ref"} Integrating the first to seventh edition of the guideline, imaging has been playing a pivotal role in the diagnosis and treatment of this disease. Especially in hospitals that cannot perform NAAT, imaging can be a powerful tool for admission screening. Therefore, grasping the imaging features of patients with COVID‐19 is of great significance for early screening and diagnosis, curbing the occurrence and development of the disease, and suppressing the speed of transmission.

Although many studies have been published on CT imaging of patients with COVID‐19, most of them were single‐center, and in the same hospital or region. Due to the different design and insufficient sample size, the imaging features of the published studies were different. Moreover, there is still lack evidence‐based medical evidence on the CT imaging features in patients with COVID‐19 to guide clinical practice. Therefore, we carried out this study to summarize the CT imaging features of COVID‐19, to provide reference for further clinical practice.

2. MATERIALS AND METHODS {#jmv25910-sec-0060}
========================

2.1. Search databases and search strategies {#jmv25910-sec-0070}
-------------------------------------------

This meta‐analysis was carried out according to Preferred Reporting Items for Meta‐Analyses of Observational Studies in Epidemiology (MOOSE) Statement.[^7^](#jmv25910-bib-0007){ref-type="ref"} PubMed, FMRS, EMbase, CNKI, WanFang databases, and VIP databases were electronically searched to collect studies about the CT imaging features of COVID‐19 from 1 January 2020 to 16 March 2020. We also manually searched the lists of included studies to avoid missing any eligible study. When duplicate studies describing the same population, the most detailed or recent study was included. There was no language restriction placed on the searches, but only literatures published online were included. The search used a combination of subject words and free words, and adjusted according to different database characteristics. The search terms included: "Coronavirus" OR "2019‐nCoV" OR "COVID‐19" OR "SARS‐CoV‐2."

2.2. Inclusion and exclusion criteria {#jmv25910-sec-0080}
-------------------------------------

The inclusion criteria were as follows: (a) cohort studies, case‐control studies, and case series studies; (b) the study population was patients diagnosed with COVID‐19; and (c) the observation indicators were the imaging findings of chest CT or HRCT.

The exclusion criteria were as follows: (a) overlapping or duplicate studies; (b) had no clinical indicators or lacking necessary data which cannot be obtained even by contacting the author; and (c) case reports and studies with a sample size less than 30.

2.3. Data extraction and quality assessment {#jmv25910-sec-0090}
-------------------------------------------

Three researchers independently searched and screened the studies, collected data, and cross‐checked. If there was a dispute, it was resolved through discussion or consultation with another researcher. The content of the data extraction included: the first author\'s surname, the date of publication of the article, study region/country, study design, sample size, age, and CT imaging features; relevant elements of bias risk assessment.

The included studies of this meta‐analyses were observational studies, so the British National Institute for Clinical Excellence (NICE)[^8^](#jmv25910-bib-0008){ref-type="ref"} was used to evaluate the study quality by two independent reviewers. This evaluation was conducted based on a set of eight criteria, and studies with a score greater than 4 were considered to be of high quality (total score = 8).

2.4. Statistical analysis {#jmv25910-sec-0100}
-------------------------

Meta‐analysis was performed using STATA 12 (StataCorp, College Station, TX). Original incidence rates *r* were transformed by the double arcsine method to make them conformed to normal distribution, and the resulting transformed rate *tr* was used in meta‐analysis. The heterogeneity between studies was analyzed using a *χ* ^2^ test (*P* \< .10) and quantified using the *I* ^2^ statistic. When no statistical heterogeneity was observed, a fixed effects model was utilized. Otherwise, potential sources of clinical heterogeneity were identified using subgroup analysis and sensitivity analyses, these sources were eliminated and the meta‐analysis was repeated using a random effects model. Pooled incidence rates *R* were back‐calculated from transformed rates *tr* using the *R* = \[sin (*tr*/2)\]^2^. A two‐tailed *P* \< .05 was considered statistically significant. Publication bias was evaluated using a funnel plot along with Egger\'s regression test and Begg\'s test.

3. RESULTS {#jmv25910-sec-0110}
==========

3.1. Literature retrieval {#jmv25910-sec-0120}
-------------------------

A total of 4532 related articles were obtained in the initial retrieval. After a detailed assessment based on the inclusion and exclusion criteria, 34 retrospective studies including 4121 patients with COVID‐19 were included[^9^](#jmv25910-bib-0009){ref-type="ref"}, [^10^](#jmv25910-bib-0010){ref-type="ref"}, [^11^](#jmv25910-bib-0011){ref-type="ref"}, [^12^](#jmv25910-bib-0012){ref-type="ref"}, [^13^](#jmv25910-bib-0013){ref-type="ref"}, [^14^](#jmv25910-bib-0014){ref-type="ref"}, [^15^](#jmv25910-bib-0015){ref-type="ref"}, [^16^](#jmv25910-bib-0016){ref-type="ref"}, [^17^](#jmv25910-bib-0017){ref-type="ref"}, [^18^](#jmv25910-bib-0018){ref-type="ref"}, [^19^](#jmv25910-bib-0019){ref-type="ref"}, [^20^](#jmv25910-bib-0020){ref-type="ref"}, [^21^](#jmv25910-bib-0021){ref-type="ref"}, [^22^](#jmv25910-bib-0022){ref-type="ref"}, [^23^](#jmv25910-bib-0023){ref-type="ref"}, [^24^](#jmv25910-bib-0024){ref-type="ref"}, [^25^](#jmv25910-bib-0025){ref-type="ref"}, [^26^](#jmv25910-bib-0026){ref-type="ref"}, [^27^](#jmv25910-bib-0027){ref-type="ref"}, [^28^](#jmv25910-bib-0028){ref-type="ref"}, [^29^](#jmv25910-bib-0029){ref-type="ref"}, [^30^](#jmv25910-bib-0030){ref-type="ref"}, [^31^](#jmv25910-bib-0031){ref-type="ref"}, [^32^](#jmv25910-bib-0032){ref-type="ref"}, [^33^](#jmv25910-bib-0033){ref-type="ref"}, [^34^](#jmv25910-bib-0034){ref-type="ref"}, [^35^](#jmv25910-bib-0035){ref-type="ref"}, [^36^](#jmv25910-bib-0036){ref-type="ref"}, [^37^](#jmv25910-bib-0037){ref-type="ref"}, [^38^](#jmv25910-bib-0038){ref-type="ref"}, [^39^](#jmv25910-bib-0039){ref-type="ref"}, [^40^](#jmv25910-bib-0040){ref-type="ref"}, [^41^](#jmv25910-bib-0041){ref-type="ref"}, [^42^](#jmv25910-bib-0042){ref-type="ref"} (Figure [1](#jmv25910-fig-0001){ref-type="fig"}).

![Flow chart of literature screening](JMV-9999-na-g001){#jmv25910-fig-0001}

3.2. Basic characteristics of included studies and quality evaluation {#jmv25910-sec-0130}
---------------------------------------------------------------------

A total of 34 retrospective studies[^9^](#jmv25910-bib-0009){ref-type="ref"}, [^10^](#jmv25910-bib-0010){ref-type="ref"}, [^11^](#jmv25910-bib-0011){ref-type="ref"}, [^12^](#jmv25910-bib-0012){ref-type="ref"}, [^13^](#jmv25910-bib-0013){ref-type="ref"}, [^14^](#jmv25910-bib-0014){ref-type="ref"}, [^15^](#jmv25910-bib-0015){ref-type="ref"}, [^16^](#jmv25910-bib-0016){ref-type="ref"}, [^17^](#jmv25910-bib-0017){ref-type="ref"}, [^18^](#jmv25910-bib-0018){ref-type="ref"}, [^19^](#jmv25910-bib-0019){ref-type="ref"}, [^20^](#jmv25910-bib-0020){ref-type="ref"}, [^21^](#jmv25910-bib-0021){ref-type="ref"}, [^22^](#jmv25910-bib-0022){ref-type="ref"}, [^23^](#jmv25910-bib-0023){ref-type="ref"}, [^24^](#jmv25910-bib-0024){ref-type="ref"}, [^25^](#jmv25910-bib-0025){ref-type="ref"}, [^26^](#jmv25910-bib-0026){ref-type="ref"}, [^27^](#jmv25910-bib-0027){ref-type="ref"}, [^28^](#jmv25910-bib-0028){ref-type="ref"}, [^29^](#jmv25910-bib-0029){ref-type="ref"}, [^30^](#jmv25910-bib-0030){ref-type="ref"}, [^31^](#jmv25910-bib-0031){ref-type="ref"}, [^32^](#jmv25910-bib-0032){ref-type="ref"}, [^33^](#jmv25910-bib-0033){ref-type="ref"}, [^34^](#jmv25910-bib-0034){ref-type="ref"}, [^35^](#jmv25910-bib-0035){ref-type="ref"}, [^36^](#jmv25910-bib-0036){ref-type="ref"}, [^37^](#jmv25910-bib-0037){ref-type="ref"}, [^38^](#jmv25910-bib-0038){ref-type="ref"}, [^39^](#jmv25910-bib-0039){ref-type="ref"}, [^40^](#jmv25910-bib-0040){ref-type="ref"}, [^41^](#jmv25910-bib-0041){ref-type="ref"}, [^42^](#jmv25910-bib-0042){ref-type="ref"} that publicated from 6 February 2020 to 12 March 2020 were included. All studies were conducted in China, 16 of the studies included patients in Hubei Province, and the remaining 18 studies included patients in other provinces. All studies received quality scores of 5 to 8, indicating high quality (Table [1](#jmv25910-tbl-0001){ref-type="table"}).

###### 

Basic characteristics of included studies

  Study                                                      Publication date   Region (China)    Sample size (n)   Study population                                                                                                      Age,[^a^](#jmv25910-tbl1-note-0003){ref-type="fn"} y   Male (n)   Outcomes   Quality score
  ---------------------------------------------------------- ------------------ ----------------- ----------------- --------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ ---------- ---------- ---------------
  Guan et al[^9^](#jmv25910-bib-0009){ref-type="ref"}        Feb 28             31 Provinces      1099              COVID‐19 patients in 552 hospitals in 31 provinces/province‐level municipalities                                      47.0                                                   640        ①②③        6
  Cheng et al[^10^](#jmv25910-bib-0010){ref-type="ref"}      Mar 12             Hubei             463               COVID‐19 patients in wuhan Jinyintan Hospital                                                                         15‐90                                                  244        ①②③④       6
  Gong et al[^11^](#jmv25910-bib-0011){ref-type="ref"}       Mar 9              Chongqing         225               COVID‐19 patients in Chongqing University Three Gorges Hospital                                                       46.35 ± 16.1                                           125        ①②③        6
  Yuan et al[^12^](#jmv25910-bib-0012){ref-type="ref"}       Mar 6              Chongqing         223               COVID‐19 patients in Chongqing Public Health Medical Center                                                           46.5 ± 16.1                                            105        ①③         6
  Zhou et al[^13^](#jmv25910-bib-0013){ref-type="ref"}       Mar 9              Wuhan             191               COVID‐19 patients in Jinyintan Hospital and Wuhan Pulmonary Hospital                                                  18‐87                                                  119        ①②③        7
  Yang et al[^14^](#jmv25910-bib-0014){ref-type="ref"}       Feb 26             Wenzhou           149               COVID‐19 patients in three tertiary hospitals of Wenzhou                                                              45.1 ± 13.4                                            81         ①②③④       7
  Wu et al[^15^](#jmv25910-bib-0015){ref-type="ref"}         Mar 3              Provinces         130               COVID‐19 patients in seven hospitals of China                                                                         25‐80                                                  78         ①②③④       7
  Bernheim et al[^16^](#jmv25910-bib-0016){ref-type="ref"}   Feb 20             4 Provinces       121               COVID‐19 patients in four centers in China                                                                            45(18‐80)                                              61         ①③④        8
  Zhao et al[^17^](#jmv25910-bib-0017){ref-type="ref"}       Feb 19             Hubei             101               COVID‐19 patients in four cities in Hunan, China                                                                      17‐75                                                  56         ①②③④       6
  Chen et al[^18^](#jmv25910-bib-0018){ref-type="ref"}       Feb 15             Wuhan             99                COVID‐19 patients in Wuhan Jinyintan Hospital                                                                         55.5 ± 13.1                                            67         ①③         6
  Xu et al[^19^](#jmv25910-bib-0019){ref-type="ref"}         Feb 28             Guangzhou         90                COVID‐19 patients in Guangzhou Eighth People\'s Hospital                                                              18‐86                                                  39         ①③④        6
  Li et al[^20^](#jmv25910-bib-0020){ref-type="ref"}         Feb 29             Chongqing/Jinan   83                COVID‐19 patients in Chongqing/Jinan provinces                                                                        45.5                                                   44         ①②③④       8
  Shi et al[^21^](#jmv25910-bib-0021){ref-type="ref"}        Feb 24             Wuhan             81                COVID‐19 patients in Wuhan Jinyintan hospital or Union Hospital of Tongji Medical College                             49.5                                                   42         ①②③④       7
  Wu et al[^22^](#jmv25910-bib-0022){ref-type="ref"}         Feb 21             Chongqing         80                COVID‐19 patients in Chongqing province                                                                               44 ± 11                                                42         ①②③④       7
  Wu et al[^23^](#jmv25910-bib-0023){ref-type="ref"}         Feb 29             Jiangsu           80                COVID‐19 patients in the First and Second People\'s Hospital of Yancheng City, the Fifth People\'s Hospital of Wuxi   46.1                                                   39         ①          8
  Fang et al[^24^](#jmv25910-bib-0024){ref-type="ref"}       Feb 25             Anhui             79                COVID‐19 patients in Infection Hospital of Anhui Provincial Hospital                                                  45.1 ± 16.1                                            45         ①          5
  Chen et al[^25^](#jmv25910-bib-0025){ref-type="ref"}       Mar 10             Wuhan             76                COVID‐19 patients in Wuhan Puren Hospital                                                                             28‐86                                                  40         ①③④        6
  Ma et al[^26^](#jmv25910-bib-0026){ref-type="ref"}         Mar 10             Anhui             75                COVID‐19 patients in 4 hospitals in Fuyang city, Anhui province                                                       43.9 ± 15.1                                            46         ①③④        7
  Pan et al[^27^](#jmv25910-bib-0027){ref-type="ref"}        Feb 6              Wuhan             63                COVID‐19 patients in Tongji hospital                                                                                  44.9 ± 15.2                                            33         ①②③        6
  Zhou et al[^28^](#jmv25910-bib-0028){ref-type="ref"}       Feb 19             Wuhan             62                COVID‐19 patients in Tongji hospital                                                                                  52.8 ± 12.2                                            39         ①②③④       6
  Wang et al[^29^](#jmv25910-bib-0029){ref-type="ref"}       Feb 25             Zhejiang          52                COVID‐19 patients in the First Affiliated Hospital, Zhejiang University School of Medicine                            13‐73                                                  29         ①②③④       6
  Xu et al[^30^](#jmv25910-bib-0030){ref-type="ref"}         Feb 25             Beijing/Hebei     50                COVID‐19 patients in 4 hospitals in Beijing/Hebei provinces                                                           43.9 ± 16.8                                            29         ①③④        6
  Liao et al[^31^](#jmv25910-bib-0031){ref-type="ref"}       Feb 26             Wuhan             42                COVID‐19 patients in Zhongnan Hospital of Wuhan University                                                            51.6                                                   29         ①②③④       6
  Xiong et al[^32^](#jmv25910-bib-0032){ref-type="ref"}      Mar 3              Wuhan             42                COVID‐19 patients in Tongji Hospital                                                                                  49.5 ± 14.1                                            25         ①②③④       5
  Liu et al[^33^](#jmv25910-bib-0033){ref-type="ref"}        Feb 18             Hubei             41                COVID‐19 patients in Xiao chang First People\'s Hospital                                                              48.45                                                  32         ①②③④       6
  Huang et al[^34^](#jmv25910-bib-0034){ref-type="ref"}      Jan 24             Wuhan             41                COVID‐19 patients in the designated hospital in Wuhan                                                                 41‐58                                                  30         ①          6
  Yu et al[^35^](#jmv25910-bib-0035){ref-type="ref"}         Feb 26             Zhejiang          40                COVID‐19 patients in Wenzhou Sixth People\'s Hospital                                                                 45.9                                                   22         ①②③        6
  Yu et al[^36^](#jmv25910-bib-0036){ref-type="ref"}         Feb 17             Beijing           40                COVID‐19 patients in the 5th Medical Centre of Chinese PLA General Hospital                                           39.9 ± 18.2                                            26         ①          6
  Zhang et al[^37^](#jmv25910-bib-0037){ref-type="ref"}      Mar 6              Hebei             40                COVID‐19 patients in Hebei provinces                                                                                  49.33 ± 14.19                                          20         ①④         5
  Cao et al[^38^](#jmv25910-bib-0038){ref-type="ref"}        Feb 28             Wuhan             36                COVID‐19 patients in Zhongnan Hospital of Wuhan University                                                            72.45 ± 6.82                                           20         ①②③④       6
  Huang et al[^39^](#jmv25910-bib-0039){ref-type="ref"}      Feb 28             Guangdong         35                COVID‐19 patients in Guangdong Second People′s Hospital                                                               44.0 ± 15.2                                            19         ①②③        6
  Wang et al[^40^](#jmv25910-bib-0040){ref-type="ref"}       Feb 19             Wuhan             32                COVID‐19 patients in The Central Hospital of Xiaogan                                                                  27‐78                                                  16         ①②③        6
  Zhong et al[^41^](#jmv25910-bib-0041){ref-type="ref"}      Feb 13             Wuhan             30                COVID‐19 patients in Zhongnan Hospital of Wuhan University                                                            50.17 ± 17.6                                           18         ①②③④       5
  Liu et al[^42^](#jmv25910-bib-0042){ref-type="ref"}        Feb 17             Wuhan             30                COVID‐19 patients in the Affiliated Hospital of Jianghan University                                                   21‐59                                                  10         ①②③        6

*Note*: ① lesion distribution; ② lesion shapes; ③ lesion density; ④ accompanying signs.

Abbreviations: COVID‐19, coronavirus disease 2019; SD, standard deviation.

Reported variously as range or mean ± SD or median, and interquartile range (IQR) values.
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3.3. Meta‐analysis results {#jmv25910-sec-0140}
--------------------------

### 3.3.1. Lesion distribution {#jmv25910-sec-0150}

There were 73.8% of the COVID‐19 patients presented bilateral lung involvement (95% CI: 65.9%‐81.1%) and multilobar involvement 67.3% (95% CI: 54.8%‐78.7%) (Figures [2](#jmv25910-fig-0002){ref-type="fig"} and [3](#jmv25910-fig-0003){ref-type="fig"}). Single lung involvement (18.7%) and single lobe involvement (14.9%) were rare. A few patients showed normal CT manifestations(8.4%) (Figure [4](#jmv25910-fig-0004){ref-type="fig"} and Table [2](#jmv25910-tbl-0002){ref-type="table"}).

![Transformed incidence rate of the indicator of bilateral lung involvement in patients with COVID‐19. COVID‐19, coronavirus disease 2019](JMV-9999-na-g002){#jmv25910-fig-0002}

![Transformed incidence rate of the indicator of multilobar involvement in patients with COVID‐19. COVID‐19, coronavirus disease 2019](JMV-9999-na-g003){#jmv25910-fig-0003}

![Transformed incidence rate of the indicator of normal CT manifestation in patients with COVID‐19. COVID‐19, coronavirus disease 2019](JMV-9999-na-g004){#jmv25910-fig-0004}

###### 

Meta‐analysis of different CT Imaging features in COVID‐19 patients

                                        Heterogeneity           Meta‐analysis                         
  ------------------------- ---- ------ --------------- ------- --------------- --------------------- --------
  Lesion distribution                                                                                 
  Single lung lesions       22   1977   \<.001          81.6%   Random          .187 (0.147, 0.231)   \<.001
  Bilateral lung lesions    28   2628   \<.001          94.9%   Random          .738 (0.659, 0.811)   \<.001
  Multilobar lesions        10   846    \<.001          92.7%   Random          .673 (0.548, 0.787)   \<.001
  Single lobe lesions       9    629    \<.001          79.6%   Random          .149 (0.092, 0.217)   \<.001
  Normal CT manifestation   13   2195   \<.001          93.3%   Random          .084 (0.042, 0.139)   \<.001
  Lesion shapes                                                                                       
  Nodular                   8    739    \<.001          96.8%   Random          .205 (0.068, 0.391)   \<.001
  Patchy                    8    2009   \<.001          94.1%   Random          .403 (0.298, 0.514)   \<.001
  Cord‐like                 6    267    \<.001          87.3%   Random          .368 (0.217, 0.534)   \<.001
  Spider web sign           11   806    \<.001          92.9%   Random          .395 (0.272, 0.526)   \<.001
  Lesion density                                                                                      
  Ground‐glass opacities    26   3574   \<.001          97.7%   Random          .681 (0.569, 0.782)   \<.001
  Consolidation             14   1637   \<.001          95.4%   Random          .320 (0.215, 0.434)   \<.001
  Air bronchogram sign      15   1075   \<.001          93.9%   Random          .447 (0.329, 0.568)   \<.001
  Crazy‐paving pattern      4    264    \<.001          95.8%   Random          .356 (0.113, 0.648)   \<.001
  Accompanying signs                                                                                  
  Pleural effusion          17   1627   .024            44.8%   Random          .053 (0.037, 0.073)   \<.001
  Pleural thickening        9    1077   \<.001          95.6%   Random          .271 (0.156, 0.405)   \<.001
  Lymphadenopathy           8    622    \<.001          82.0%   Random          .054 (0.022, 0.098)   \<.001

Abbreviations: CI, confidence interval; COVID‐19, coronavirus disease 2019; CT, computed tomography.
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### 3.3.2. Lesion shapes {#jmv25910-sec-0160}

The lesion shapes included patchy (40.3%, 95%CI: 29.8%‐51.4%), cord‐like (36.8%, 95% CI: 21.7%‐53.4%), nodular(20.5%, 95% CI: 6.8%‐39.1%), and spider web sign (39.5%, 95% CI: 27.2%‐52.6%) (Table [2](#jmv25910-tbl-0002){ref-type="table"}).

### 3.3.3. Lesion density {#jmv25910-sec-0170}

The most common lesion density change was ground‐glass opacities (68.1%, 95% CI: 56.9%‐78.2%) (Figure [5](#jmv25910-fig-0005){ref-type="fig"}). Other changes included air bronchogram sign (44.7%, 95% CI: 32.9%‐56.8%), crazy‐paving pattern(35.6%, 95% CI: 11.3%‐64.8%), and consolidation (32.0%, 95% CI: 21.5%‐43.4%) (Table [2](#jmv25910-tbl-0002){ref-type="table"}).

![Transformed incidence rate of the indicator of ground‐glass opacities in patients with COVID‐19. COVID‐19, coronavirus disease 2019](JMV-9999-na-g005){#jmv25910-fig-0005}

### 3.3.4. Accompanying signs {#jmv25910-sec-0180}

Pleural thickening (27.1%, 95% CI: 15.6%‐40.5%) was found in some patients. Lymphadenopathy (5.4%, 95% CI: 0.022‐0.098), and pleural effusion (5.3%, 95% CI: 3.7%‐7.3%) were rare (Figure [6](#jmv25910-fig-0006){ref-type="fig"} and Table [2](#jmv25910-tbl-0002){ref-type="table"}).

![Transformed incidence rate of the indicator of pleural effusion in patients with COVID‐19. COVID‐19, coronavirus disease 2019](JMV-9999-na-g006){#jmv25910-fig-0006}

### 3.3.5. Subgroup analysis {#jmv25910-sec-0190}

This study showed significant heterogeneity. To explore the source of heterogeneity, subgroup analysis was performed. The results showed that the analysis results of the subgroups were basically consistent with the overall results, and there was no significant difference between the heterogeneity of the subgroups and the overall heterogeneity, which indicated that the study subject\'s location and sample size were not the main sources of heterogeneity (Table [3](#jmv25910-tbl-0003){ref-type="table"}).

###### 

Subgroup analysis of different CT manifestations in COVID‐19 patients

                                        Heterogeneity           Meta‐analysis                         
  ------------------------- ---- ------ --------------- ------- --------------- --------------------- --------
  Normal CT manifestation                                                                             
  Hebei province            1    101    \<.001          94.4%   Random          .103 (0.050, 0.174)   .067
  Other provinces           12   094    \<.001          80.8%   Random          .022 (0.042, 0.139)   \<.001
  Bilateral lung lesions                                                                              
  Hebei province            15   1367   .001            61.5%   Random          .784 (0.743, 0.822)   \<.001
  Other provinces           13   1261   \<.001          97.3%   Random          .690 (0.524, 0.834)   \<.001
  Ground‐glass opacities                                                                              
  Hebei province            13   1271   \<.001          96.5%   Random          .688 (0.536, 0.821)   \<.001
  Other provinces           13   2303   \<.001          98.3%   Random          .674 (0.503, 0.823)   \<.001
  Pleural effusion                                                                                    
  Hebei province            10   974    .249            21.3%   Random          .036 (0.017, 0.063)   \<.001
  Other provinces           7    653    .002            66.8%   Random          .073 (0.054, 0.095)   \<.001

Abbreviations: CI, confidence interval; COVID‐19, coronavirus disease 2019; CT, computed tomography.
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### 3.3.6. Sensitivity analysis {#jmv25910-sec-0200}

Sensitivity analysis was performed for the observation indicators of bilateral lung involvement, and statistics were recombined after excluding each study in turn. The results did not change substantially, suggesting that the results were stable (Figure [7](#jmv25910-fig-0007){ref-type="fig"}).

![Sensitivity analysis of the indicator of bilateral lung involvement in patients with COVID‐19. COVID‐19, coronavirus disease 2019](JMV-9999-na-g007){#jmv25910-fig-0007}

3.4. Publication bias {#jmv25910-sec-0210}
---------------------

The *P* values derived using Egger\'s and Begg\'s tests for all the observation indicators showed no obvious publication bias (Table [4](#jmv25910-tbl-0004){ref-type="table"}). A funnel plot regarding the observation indicators of bilateral lung involvement showed the *P* values of Egger\'s and Begg\'s tests were .859 and .277, respectively, suggesting that the publication bias was not existed (Figure [8](#jmv25910-fig-0008){ref-type="fig"}).

###### 

Evaluation of publication bias using Egger\'s and Begg\'s tests

  Characteristic           *P* (Egger\'s)   *P* (Begg\'s)   Characteristic            *P* (Egger\'s)   *P* (Begg\'s)
  ------------------------ ---------------- --------------- ------------------------- ---------------- ---------------
  Single lung lesions      .037             .090            Ground‐glass opacities    .003             .552
  Bilateral lung lesions   .859             .277            Consolidation             .053             .228
  Multilobar lesions       .160             .210            Air bronchogram sign      .616             .960
  Single lobe lesions      .952             .754            Crazy‐paving pattern      .429             .734
  Nodular                  .667             .902            Pleural effusion          .854             .869
  Patchy                   .328             .386            Pleural thickening        .062             .910
  Cord‐like                .995             .851            Lymphadenopathy           .121             .386
  Spider web sign          .049             .138            Normal CT manifestation   .404             .964

Abbreviation: CT, computed tomography.

John Wiley & Sons, Ltd.

This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

![Evaluation of publication bias using a funnel plot based on the incidence rate of bilateral lung involvement](JMV-9999-na-g008){#jmv25910-fig-0008}

4. DISCUSSION {#jmv25910-sec-0220}
=============

2019‐nCoV is one type of β‐coronavirus with a positive‐stranded single‐stranded RNA.[^43^](#jmv25910-bib-0043){ref-type="ref"} In the past two decades, humans have experienced three fatal coronavirus infections, including severe acute respiratory syndrome (SARS) in 2002, Middle East respiratory syndrome (MERS) in 2012, and COVID‐19.[^44^](#jmv25910-bib-0044){ref-type="ref"} The fatality rate of COVID‐19 was lower than SARS (9.6%) and MERS (35%),[^45^](#jmv25910-bib-0045){ref-type="ref"}, [^46^](#jmv25910-bib-0046){ref-type="ref"}, [^47^](#jmv25910-bib-0047){ref-type="ref"} but it\'s transmission ability was stronger.[^48^](#jmv25910-bib-0048){ref-type="ref"} Therefore, early diagnosis, isolation, and treatment of suspected or infected patients are of great significance for the prevention and control of COVID‐19. The current gold standard for COVID‐19 diagnosis is positive results of NAAT, viral gene sequencing, positive serum novel coronavirus‐specific Immunoglobulin M antibodies and Immunoglobulin G antibodies. However, such diagnostic methods also have some limitations, and not all hospitals can implement them. For example, NAAT can only make a positive diagnosis, but cannot judge the severity of the patients; when the viral load is low, it would make a false‐negative results; due to the sudden increase of a large number of suspected cases and the shortage of nucleic acid testing reagents, many patients will not be diagnosed in time.[^49^](#jmv25910-bib-0049){ref-type="ref"} However, compared with various limitations of NAAT, the lung CT examinations is timely, rapid, and has a high positive rate.[^49^](#jmv25910-bib-0049){ref-type="ref"}, [^50^](#jmv25910-bib-0050){ref-type="ref"} Most important of all, CT can be carried out in most hospitals. So thin‐layer CT scan of the lung is of great significance for the early diagnosis and assessment of COVID‐19.

In this study, we collected the latest articles up to 16 March 2020, included 34 retrospective studies[^9^](#jmv25910-bib-0009){ref-type="ref"}, [^10^](#jmv25910-bib-0010){ref-type="ref"}, [^11^](#jmv25910-bib-0011){ref-type="ref"}, [^12^](#jmv25910-bib-0012){ref-type="ref"}, [^13^](#jmv25910-bib-0013){ref-type="ref"}, [^14^](#jmv25910-bib-0014){ref-type="ref"}, [^15^](#jmv25910-bib-0015){ref-type="ref"}, [^16^](#jmv25910-bib-0016){ref-type="ref"}, [^17^](#jmv25910-bib-0017){ref-type="ref"}, [^18^](#jmv25910-bib-0018){ref-type="ref"}, [^19^](#jmv25910-bib-0019){ref-type="ref"}, [^20^](#jmv25910-bib-0020){ref-type="ref"}, [^21^](#jmv25910-bib-0021){ref-type="ref"}, [^22^](#jmv25910-bib-0022){ref-type="ref"}, [^23^](#jmv25910-bib-0023){ref-type="ref"}, [^24^](#jmv25910-bib-0024){ref-type="ref"}, [^25^](#jmv25910-bib-0025){ref-type="ref"}, [^26^](#jmv25910-bib-0026){ref-type="ref"}, [^27^](#jmv25910-bib-0027){ref-type="ref"}, [^28^](#jmv25910-bib-0028){ref-type="ref"}, [^29^](#jmv25910-bib-0029){ref-type="ref"}, [^30^](#jmv25910-bib-0030){ref-type="ref"}, [^31^](#jmv25910-bib-0031){ref-type="ref"}, [^32^](#jmv25910-bib-0032){ref-type="ref"}, [^33^](#jmv25910-bib-0033){ref-type="ref"}, [^34^](#jmv25910-bib-0034){ref-type="ref"}, [^35^](#jmv25910-bib-0035){ref-type="ref"}, [^36^](#jmv25910-bib-0036){ref-type="ref"}, [^37^](#jmv25910-bib-0037){ref-type="ref"}, [^38^](#jmv25910-bib-0038){ref-type="ref"}, [^39^](#jmv25910-bib-0039){ref-type="ref"}, [^40^](#jmv25910-bib-0040){ref-type="ref"}, [^41^](#jmv25910-bib-0041){ref-type="ref"}, [^42^](#jmv25910-bib-0042){ref-type="ref"} involving 4121 patients with COVID‐19 distribution in 31 provincial‐level regions in China. The results of meta‐analysis showed that most patients presented bilateral lung involvement or multilobar involvement. The most typical manifestations of chest CT were ground‐glass opacities, patchy, cord‐like, and nodular. Pleural thickening was found in some patients. Lymphadenopathy and pleural effusion were rare. These were basically consistent with the guideline for the diagnosis and treatment of COVID‐19.[^6^](#jmv25910-bib-0006){ref-type="ref"} Lin et al[^51^](#jmv25910-bib-0051){ref-type="ref"} also pointed out that the imaging findings of lungs appeared earlier than clinical symptoms, and the CT findings of lungs changed dynamically as the disease progressed, so CT imaging can reveal disease progression. Therefore, in different stages of the disease, CT can be used to evaluate the severity of the disease and efficacy of the treatment.[^17^](#jmv25910-bib-0017){ref-type="ref"} For patients with an epidemiological history, a CT scan of the lung should be performed even if there are no clinical symptoms or NAAT negative. If patients with epidemiological history are found that the CT of the lung has typical features such as ground‐glass opacities of the bilateral lungs or multiple lobes, they should be highly suspected they are with COVID‐19. The faster isolation measures should be taken, and further diagnosis and treatment should be performed as soon as possible to avoid the widespread of the disease or loss of treatment opportunities.

This study has several strengths including its large sample size and high quality of included studies. We conducted subgroup analysis according to studies\' region and sample size. We also conducted sensitivity analysis by excluding each study one by one. The results did not change significantly, indicating the reliability and stability of our results. Nevertheless, some limitations should be noted in our meta‐analysis. First, most of our included studies are single‐center, which may have admission bias and selection bias. Second, most of our included studies did not clarify the inclusion or exclusion criteria, the course and severity of disease were not the same. Third, all the included studies were retrospective studies, we were unable to control the influence of confounding factors. Lastly, this meta‐analysis indicated a significant heterogeneity between the studies. But the subgroup analysis fails to eliminate all sources of heterogeneity, which may affect the accuracy of the results of meta‐analysis.

5. CONCLUSION {#jmv25910-sec-0230}
=============

To sum up, most patients presented bilateral lung involvement or multilobar involvement. The most common changes were ground‐glass opacities and air bronchogram sign. Other common changes included patchy, spider web sign, and so forth. Lymphadenopathy and pleural effusion were rare. But due to the quality and quantity of included studies, the above conclusions need to be confirmed by more high‐quality studies.
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